Time-kill and disk synergy studies with non-beta-lactams against non-multiresistant methicillin-resistant Staphylococcus aureus [2]

Pathology

Volumn 38, Issue 3, 2006, Pages 259-261

  Gosbell, Iain B ^a,b  

^a SYDNEY SOUTH WEST AREA HEALTH SERVICE   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; FUSIDIC ACID; GENTAMICIN; RIFAMPICIN; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

BACTERICIDAL ACTIVITY; CLINICAL TRIAL; DISEASE PREDISPOSITION; DRUG POTENTIATION; HUMAN; LETTER; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

EID: 33745064172     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020600699235     Document Type: Article

References (12)

1. Gosbell IB, Mercer JL, Neville SA, et al. Non-multiresistant and multiresistant methicillin-resistant Staphylococcus aureus in community-acquired infections. Med J Aust 2001; 174: 627-30.
2. Rochon-Edouard S, Pestel-Caron M, Lemeland JF, Caron F. In vitro synergistic effects of double and triple combinations of beta-lactams, vancomycin, and netilmicin against methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 2000; 44: 3055-60.
3. National Committee for Clinical Laboratory Standards (NCCLS). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard, Fifth Edition. Wayne, Pennsylvania: NCCLS, 2000. Document M7-A5.
4. National Committee for Clinical Laboratory Standards (NCCLS). Methods for Determining Bactericidal Activity of Antimicrobial Agents: Approved Guideline. Wayne, Pennsylvania: NCCLS, 1999. Document M26-A.
5. Marcinak JF, Frank AL. Treatment of community-acquired methicillin-resistant Staphylococcus aureus in children. Curr Opin Infect Dis 2003; 16: 265-9.
6. Grim SA, Rapp RP, Martin CA, Evans ME. Trimethoprimsulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus. Pharmacotherapy 2005; 25: 253-64.
7. Ruhe JJ, Monson T, Bradsher RW, Menon A. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: Case series and review of the literature. Clin Infect Dis 2005; 40: 1429-34.
8. Donaldson A, Chan RC, Gosbell IB. Community-acquired methicillin- resistant Staphylococcus aureus bone and joint infections: development of rifampicin resistance. Med J Aust 2006; 184: 196.
9. Ng J, Gosbell IB. Successful oral pristinamycin therapy for osteoarticular infections due to methicillin-resistant Staphylococcus aureus (MRSA) and other Staphylococcus spp. J Antimicrob Chemother 2005; 55: 1008-12.
10. Raghavan M, Linden PK. Newer treatment options for skin and soft tissue infections. Drugs 2004; 64: 1621-42.
11. Gosbell IB. Methicillin-resistant Staphylococcus aureus. Impact on dermatology practice. Am J Clin Dermatol 2004; 5: 239-59.
12. Munckhof WJ, Kleinschmidt SL, Turnidge JD. Resistance development in community-acquired strains of methicillin-resistant Staphylococcus aureus: an in vitro study. Int J Antimicrob Agent 2004; 24: 605-8.